24 completed. 24 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 24 | Completed 24 |
| Phase 3 | 3 | Completed 3 |
| Phase 1 | 2 | Completed 2 |
Follow Keratoconjunctivitis: new trials by email Literature Review of Keratoconjunctivitis trials Research Report on Keratoconjunctivitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease INV-102, Vehicle - Dry Eye Disease | Phase 2 | Completed | Invirsa, Inc. | 109 | 2024-03-27 | 2026-09-18 |
| Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease INV-102, Vehicle - Dry Eye Disease | Phase 1 / Phase 2 | Completed | Invirsa, Inc. | 84 | 2022-08-30 | 2026-09-18 |
| Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine Ophthalmic Topical Cream, Dose 2, Pilocarpine Ophthalmic Topical Cream, Dose 3 - Dry Eye Disease, Kerato Conjunctivitis Sicca | Phase 2 | Completed | Glaukos Corporation | 226 | 2022-01-03 | 2023-07-12 |
| Levocarnitine for Dry Eye in Sjogren's Syndrome Levocarnitine, Placebo - Sjogren's Syndrome, Keratoconjunctivitis Sicca | Phase 2 | Completed | Vanderbilt University Medical Center | 15 | 2021-11-17 | 2025-12-04 |
| Mesenchymal Stem Cell Therapy of Dry Eye Disease in Patients With Sjögren's Syndrome ASCs, Cryostor CS10 - Keratoconjunctivitis Sicca, in Sjogren's Syndrome | Phase 2 | Completed | Copenhagen University Hospital, Rigshospitalet | 40 | 2020-11-03 | 2023-03-08 |
| A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease ECF843, ECF843 vehicle - Dry Eye | Phase 2 | Completed | Novartis Pharmaceuticals | 718 | 2020-10-06 | 2025-01-28 |
| Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome 0.05% Voclosporin Ophthalmic Solution (VOS), 0.10% VOS, 0.20% VOS - Dry Eye Syndrome, Keratoconjunctivitis Sicca | Phase 2 / Phase 3 | Completed | Aurinia Pharmaceuticals Inc. | 508 | 2019-10-14 | 2021-12-10 |
| Effects of RP101 in Post-menopausal Women With Dry Eye Syndrome RP101 - Dry Eye Syndromes | Phase 2 | Completed | Redwood Pharma AB | 104 | 2019-01-18 | 2019-12-20 |
| Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca OTX-101 0.05%, OTX-101 0.09%, Vehicle - Keratoconjunctivitis Sicca, Dry Eye Disease | Phase 2 / Phase 3 | Completed | Sun Pharmaceutical Industries Limited | 455 | 2014-09-01 | 2022-08-29 |
| Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease KPI-121, Placebo - Dry Eye Syndromes, Keratoconjunctivitis Sicca | Phase 2 | Completed | Kala Pharmaceuticals, Inc. | 150 | 2014-06-01 | 2021-01-06 |
| A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES) Low Dose 0.155µg/mL SkQ1 ophthalmic solution, High Dose 1.55µg/mL SkQ1 ophthalmic solution, Placebo (Vehicle) opthalmic solution - Keratoconjunctivitis Sicca | Phase 2 | Completed | Mitotech, SA | 91 | 2014-04-01 | 2020-11-02 |
| Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, Placebo Ophthalmic Solution - Chronic Graft-versus-host Disease | Phase 2 | Completed | Rigel Pharmaceuticals | 35 | 2014-03-01 | 2016-10-10 |
| Safety and Efficacy of PG101 for Dry Eye Syndrome PG101 - Dry Eye Syndrome | Phase 1 / Phase 2 | Completed | Rhodes Pharmaceuticals, L.P. | 72 | 2013-12-01 | 2014-03-05 |
| To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, Placebo - Keratoconjunctivitis Sicca | Phase 2 | Completed | Rigel Pharmaceuticals | 204 | 2013-07-01 | 2016-10-03 |
| Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease) Lotemax, Restasis, Soothe® Lubricant Eye Drops - Keratoconjunctivitis Sicca | Phase 2 | Completed | Bausch & Lomb Incorporated | 102 | 2013-05-17 | 2019-08-30 |
| Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea rebamipide 2% ophthalmic suspension, placebo eye drops - Keratoconjunctivitis Sicca, Dry Eye | Phase 2 | Completed | Kubota Vision Inc. | 116 | 2010-02-01 | 2012-01-11 |
| Dry Eye Assessment and Management: Feasibility Study Omega-3 EFA Supplement, Olive Oil - Dry Eye Syndromes, Keratoconjunctivitis Sicca | Phase 2 / Phase 3 | Completed | Asbell, Penny, M.D. | 23 | 2010-01-01 | 2012-08-23 |
| Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye rebamipide 2% ophthalmic suspension, placebo eye drops - Dry Eye Syndromes, Keratoconjunctivitis Sicca | Phase 2 | Completed | Kubota Vision Inc. | 220 | 2009-12-01 | 2012-01-11 |
| Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome AT01, AT02, AT03 - Dry Eye Syndromes, Keratoconjunctivitis Sicca | Phase 2 | Completed | Dhp Korea Co., Ltd. | 72 | 2008-11-01 | 2010-04-02 |
| Safety and Efficacy Study of RX-10045 on the Signs and Symptoms of Dry Eye RX-10045, Placebo - Dry Eye Syndrome | Phase 2 | Completed | Resolvyx Pharmaceuticals, Inc | 232 | 2008-11-01 | 2010-09-24 |
Showing 20 of 24. Sign in to see all of them.
Keratoconjunctivitis Sicca (23) · Dry Eye Syndromes (20) · Sjogren's Syndrome (3) · Bronchiolitis Obliterans Syndrome (1) · Corneal Diseases (1) · Eye Diseases (1) · Fatigue (1) · Hyperemia (1) · Inflammation (1) · Keratitis (1) · Pain (1) · Xerophthalmia (1) · Xerostomia (1)
Conjunctival Diseases (24) · Conjunctivitis (24) · Lacrimal Apparatus Diseases (24) · Corneal Diseases (23) · Eye Diseases (23) · Keratitis (23) · Dry Eye Syndromes (4) · Immune System Diseases (4) · Mouth Diseases (4) · Salivary Gland Diseases (4) · Stomatognathic Diseases (4) · Arthritis (3) · Arthritis, Rheumatoid (3) · Autoimmune Diseases (3)
Loteprednol Etabonate (2) · rebamipide (2) · CF101 (1) · Carnitine (1) · Cyclosporine (1) · Cyclosporins (1) · Gels (1) · Health Services Needs and Demand (1) · Olive Oil (1) · Rituximab (1) · Sodium Chloride (1) · isopropyl 5,12-hydroxypentadeca-8,10-dien-6,14-diynoate (1) · pimecrolimus (1)
Invirsa, Inc. (2) · Kubota Vision Inc. (2) · Rigel Pharmaceuticals (2) · Asbell, Penny, M.D. (1) · Aurinia Pharmaceuticals Inc. (1) · Bausch & Lomb Incorporated (1) · Can-Fite BioPharma (1) · Copenhagen University Hospital, Rigshospitalet (1) · Dhp Korea Co., Ltd. (1) · Glaukos Corporation (1) · Kala Pharmaceuticals, Inc. (1) · Mitotech, SA (1) · National Eye Institute (NEI) (1) · Novartis (1) · Novartis Pharmaceuticals (1)
United States (19) · Denmark (2) · Austria (1) · Germany (1) · Hungary (1) · Israel (1) · South Korea (1)
Gail Torkildsen, MD (2) · Robert Shalwitz, MD (2) · Anne Marie Lynge Pedersen, PhD, DDS (1) · Christine Shieh, MD (1) · Daniel Magilavy, MD (1) · David Evans, OD (1) · Gail Torkildsen, M.D. (1) · Gary Foulks, Dr. (1) · Gregg Berdy, MD (1) · Hungwon Tchah,, MD (1) · Irit Bareket, MD (1) · Jeffrey Whitsett, MD (1) · Jodi Luchs, MD (1) · Joel Geffin, MD (1) · John Lonsdale, MD (1)
PMID 20304499, PMID 26733410, PMID 32826644, PMID 33710587, PMID 36944128
R34EY017626 (1)